Fludarabine Phosphate (CAS 75607-67-9) Suppliers and Product Information

Fludarabine phosphate is an antimetabolite used for the treatment of chronic lymphocytic leukemia (CLL) and low-grade lymphoma. It acts by inhibiting DNA synthesis and functions as a DNA chain terminator once incorporated into DNA. The compound is rapidly dephosphorylated to fludarabine in the body and then rephosphorylated intracellularly to its active form.

Frequently Asked Questions about Fludarabine Phosphate

Q: What is the main use of Fludarabine phosphate?

A: Fludarabine phosphate is primarily used for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent-containing regimen.

Q: How does Fludarabine phosphate work?

A: Fludarabine phosphate is a prodrug that is rapidly dephosphorylated to fludarabine and then phosphorylated intracellularly to its active form. It inhibits DNA synthesis by interfering with enzymes like DNA polymerase, ribonucleotide reductase, and DNA primase, ultimately leading to cell death.

Q: What are the main side effects of Fludarabine phosphate?

A: The main side effects include bone marrow suppression, which can lead to anemia, thrombocytopenia, and neutropenia. Other potential side effects may include nausea, vomiting, and an increased risk of infections due to immunosuppression.

Q: How is Fludarabine phosphate administered?

A: Fludarabine phosphate is typically administered intravenously. The usual dosage regimen is 25 mg/m² daily for 5 consecutive days, repeated every 28 days. However, the exact dosage and schedule may vary based on individual patient factors and response to treatment.